EMA Authorised: Erelzi (etanercept) — Sandoz GmbH

View source ↗

Summary

The EMA authorised Erelzi (etanercept) by Sandoz GmbH as a biosimilar to treat several inflammatory conditions including rheumatoid arthritis, psoriatic arthrit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Juvenile Idiopathic Arthritis
• Plaque Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• Erelzi (etanercept)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Psoriatic;Psoriasis;Arthritis, Juvenile Rheumatoid;Arthritis, Rheumatoid;Spondylitis, Ankylosing. MAH: Sandoz GmbH. Decision date: 16/12/2025